Genentech news from FiercePharma
NewsAvastin-Lucentis trial may reshape pharma
We thought the head-to-head trial of Avastin and Lucentis for age-related macular degeneration was a big deal for Genentech, which Read more...
ALSO NOTED: Forest takes charge on Azor split; GSK launches Tykerb-Herceptin trials;
> Forest Laboratories will take a $44.1 million charge on termination of its deal to co-promote the hypertension drug Azor with Daiichi Sankyo. Read more...
SPOTLIGHT: Rituxan falls short in lupus trial
In a big disappointment for Genentech and Biogen Idec, Rituxan failed its late-stage test against lupus. Already approved for non-Hodgkins lymphoma and rheumatoid arthritis treatment, Rituxan might Read more...
Stanley: Erbitux outperformed Avastin
Morgan Stanley got a juicy scoop on the Avastin versus Erbitux boxing match: Genentech's Avastin faces news that as-yet-unpublished data shows Erbitux delivering an "unexpected survival Read more...
SPOTLIGHT: Abbott edges Genentech in CEO tourney
Remember the Pharma CEO tournament bracket the Wall Street Journal Health Blog came up with a few Read more...
Abbott wins pharma pay prize (so far)
This may be the biggest Pharma Chief paycheck we've seen so far: Abbott Laboratories' CEO Miles White (photo) made $33.4 Read more...
SPOTLIGHT: Who's the best CEO of them all?
Who'll brave the pitfalls of generic competition and restless shareholders and pipeline pressure to be the last Big Pharma/Big Biotech CEO standing? That's what the WSJ Health Blog is asking with a Read more...
Wyeth, Pfizer chiefs see pay decline
Here's the latest installment in the exciting serial entitled "Pharma Paycheck, or Which Way But Up?" For recently retired Wyeth Read more...
High-priced meds spur dosing debate
What's a drug worth? In the case of Cerezyme, a remedy for a rare inherited enzyme deficiency known as Gaucher disease, the answer is $300,000 a year. But experts are questioning whether lower doses Read more...
ALSO NOTED: Novartis sued over withdrawn child cold meds; Teva to expand, hire in Czech Republic;
In what could be a harbinger of more lawsuits over the OTC cold meds for children that FDA warned against and companies withdrew last fall, a California mother sued Novartis over its Triaminic Read more...
| Press ReleasesGenentech Provides Update on “AVAiL” Phase III Study of Avastin Genentech Provides Update on “AVAiL” Phase III Study of Avastin Plus Chemotherapy in First-Line, Advanced, Non-Squamous, Non-Small Cell Lung Cancer SOUTH SAN FRANCISCO, Calif. -- Genentech today Read more... PRESS RELEASE: Genentech Provides Update From Avastin FDA Advisory Meeting Genentech Provides Update From Avastin FDA Advisory Meeting Gaithersburg, Md. -- December 5, 2007 -- Genentech announced today that the Oncologic Drugs Advisory Committee (ODAC) appointed by the Read more... PRESS RELEASE: Genentech, Says Avastin Shows Promise for Brain Cancer Genentech, Says Avastin Shows Promise for Brain Cancer DALLAS -- Genentech today announced that both study arms of a randomized, multi-center Phase II clinical study of Avastin® (bevacizumab) Read more... PRESS RELEASE: Genentech President Defends Company’s Decision to Embargo Avastin Sales to Compounding Pharmacies Genentech President Defends Company’s Decision to Embargo Avastin Sales to Compounding Pharmacies Susan Desmond-Hellmann, MD, MPH, president of product development for Genentech, said she came to Read more... PRESS RELEASE: Genentech Announces Third Quarter 2007 Results Genentech Announces Third Quarter 2007 Results -- Genentech's Completion of Tanox Acquisition Reflected in Q3 Results -- South San Francisco, Calif. -- October 15, 2007 -- Read more... |
Get more Genentech coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight